A Metabolomic Study of Polycystic Ovary Syndrome With Insulin Resistance and Its Relationship With TCM Syndrome Types

NCT ID: NCT02992093

Last Updated: 2016-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-31

Study Completion Date

2020-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The type-2 diabetes mellitus(T2DM), metabolic syndrome, cardiovascular disease complications induced by polycystic ovary syndrome(PCOS) with insulin resistance(IR), which become serious threat to public health. In this observational study, obese patients with PCOS,nonobese patients with PCOS, PCOS patients with impaired glucose tolerance(IGT), PCOS patients with type-2 diabetes mellitus(T2DM), and healthy volunteers would enrolled into this study, through the Liquid Chromatography-Mass Spectrometry coupled to Mass Spectrometry( LC-MS/MS)and Rapid Resolution Liquid Chromatography(RRLC) and Quadrupole Linear Trap(QTRAP)Mass Spectrometry coupled to Mass Spectrometry (MS/MS)analysis of serum samples collected from PCOS patients and healthy volunteers to screen the biomarker of diagnosis for PCOS with insulin resistance, to explore the correlation between traditional chinese medicine (TCM) syndrome(phlegm, kidney yin deficiency, kidney yang deficiency, qi stagnation and blood stasis,dampness-heat of liver channel)and metabolites of PCOS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. The selection of research subjects: All the subjects collect from Fujian Maternity and Child Health Hospital.
2. The participants will be divided into five groups:obese with PCOS,nonobese with PCOS,PCOS with IGT,PCOS with T2DM,healthy volunteers.the syndrome type of PCOS will be divided into five types: phlegm, kidney yin deficiency, kidney yang deficiency, liver qi stagnation and blood stasis syndrome, dampness-heat of liver channel.
3. Ethical requirements and subjects' informed consent Before clinical trials begin, the program needs to be approved by the ethics committee to approve and sign the approval.The subjects need fully aware of the clinical trial and are given sufficient time to consider whether they are willing to participate in the trial, and to sign the informed consent form.
4. Indicator test (the cost of all health volunteers are paid by the research) (1)Physical examination: blood pressure, height, body weight,waist circumference,hip circumference,body mass index(BMI),waist-hip ratio(WHR).

(2)Endocrine hormones: collect serum from all the subjects,use the enzyme linked immunosorbent assay (ELISA) method to detect the level of serum follicle-stimulating hormone(FSH),luteinizing hormone(LH),prolactin(PRL),estradiol(E2),testosterone(T). Blood lipid: glycerin three vinegar (TG), cholesterol (CHOL) detect by enzymatic method, low density lipoprotein (LDL-C), high density lipoprotein (HDL-C) detect by the turbidity method. Glucose tolerance and insulin release test after glucose loading: all subjects were fasting for 8 to 10 h, check the fasting blood glucose(FBG)and fasting insulin (FINS).The oral glucose tolerance test(OGTT)and insulin release test were performed in the next morning.

5.Study on the characteristics of metabolism

(1)Through the sample pretreatment method, analyzes the optimization of the condition of mass spectrometry, according to the requirements of the metabolism to establish the blood sample LC-MS/MS metabolism analysis method.(2)Carry out the analysis of metabolism and data collection.(3)Model building and data analysis(4)Use RRLC and QTRAP type MS/MS with positive and negative ion detection mode with the combination of hyphenated techniques, combined with the method of data statistics,to establish multiple reaction monitoring(MRM) detection, to verify the precision and sensitivity of the method.

6.Statistical methods: All data use statistical product and service solutions18.0(SPSS18.0)software package for statistical analysis. According to the character of clinical trial data (measurement, classification and grade data), select the appropriate statistical analysis method.receiver operating characteristic curve(ROC) analysis of the potential metabolites selected from the targeting metabolic biomarker.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PCOS

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Polycystic ovary syndrome Metabonomics Traditional Chinese medicine syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

obese with PCOS

all the indicators

all the indicators

Intervention Type OTHER

BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

nonobese with PCOS

all the indicators

all the indicators

Intervention Type OTHER

BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

PCOS with IGT

all the indicators

all the indicators

Intervention Type OTHER

BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

PCOS with T2DM

all the indicators

all the indicators

Intervention Type OTHER

BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

Healthy volunteers

all the indicators

all the indicators

Intervention Type OTHER

BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

all the indicators

BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam consensus criteria recommended by European Society of Human Reproduction and Embryology and American Society for Reproductive Medicine in 2003(2 out of 3):Oligo-and/or anovulation;Clinical and/or biochemical signs of hyperandrogenism;Polycystic ovaries.
2. Diagnostic criteria for insulin resistance: use the HOMA model to evaluate insulin resistance. The HOMA index of insulin resistance (HOMA-IR) = (fasting blood glucose (mmol/L)× fasting insulin (mIU/L) /22.5.
3. voluntary subjects

Exclusion Criteria

1. the exclusion of other causes of Kaohsiung hormones, such as congenital adrenal hyperplasia, Cushing syndrome, androgen secreting tumors, and other diseases caused by ovulation disorders, such as hyperprolactinemia, premature ovarian failure, pituitary or hypothalamus closed by etc;
2. exclusion of organic disease or other endocrine diseases;
3. with liver and kidney, cerebral blood vessels, cardiovascular and hematopoietic disorders, such as primary disease, mental patients;
4. patients who had been treated with steroids in nearly three months , such as the birth control pill, and corticosteroids.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fujian Maternity and Child Health Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jinbang Xu

Role: PRINCIPAL_INVESTIGATOR

Fujian Maternity and Child Health Hosptial

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fujian Maternity and Child Health Hosptial

Fuzhou, Fujian, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jinbang Xu

Role: CONTACT

Phone: 13559958096

Email: [email protected]

Jingjing Dun

Role: CONTACT

Phone: 18520124299

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jinbang Xu

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Suvarna Y, Maity N, Kalra P, Shivamurthy MC. Comparison of efficacy of metformin and oral contraceptive combination of ethinyl estradiol and drospirenone in polycystic ovary syndrome. J Turk Ger Gynecol Assoc. 2016 Jan 12;17(1):6-9. doi: 10.5152/jtgga.2016.16129. eCollection 2016.

Reference Type RESULT
PMID: 27026772 (View on PubMed)

Victor VM, Rovira-Llopis S, Banuls C, Diaz-Morales N, Martinez de Maranon A, Rios-Navarro C, Alvarez A, Gomez M, Rocha M, Hernandez-Mijares A. Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase. PLoS One. 2016 Mar 23;11(3):e0151960. doi: 10.1371/journal.pone.0151960. eCollection 2016.

Reference Type RESULT
PMID: 27007571 (View on PubMed)

Sathyapalan T, Atkin SL. Recent advances in cardiovascular aspects of polycystic ovary syndrome. Eur J Endocrinol. 2012 Apr;166(4):575-83. doi: 10.1530/EJE-11-0755. Epub 2011 Nov 17.

Reference Type RESULT
PMID: 22096112 (View on PubMed)

Chen L, Xu WM, Zhang D. Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome. Fertil Steril. 2014 Oct;102(4):1167-1174.e4. doi: 10.1016/j.fertnstert.2014.06.027. Epub 2014 Jul 23.

Reference Type RESULT
PMID: 25064406 (View on PubMed)

Wehr E, Gruber HJ, Giuliani A, Moller R, Pieber TR, Obermayer-Pietsch B. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab. 2011 Jun;96(6):E986-90. doi: 10.1210/jc.2011-0031. Epub 2011 Apr 6.

Reference Type RESULT
PMID: 21470992 (View on PubMed)

Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, Zhang CM, Wang Y, Liu P, Tu BB, Zhang X, Qiao J. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med. 2012 Nov 30;10:153. doi: 10.1186/1741-7015-10-153.

Reference Type RESULT
PMID: 23198915 (View on PubMed)

Collins FS, Green ED, Guttmacher AE, Guyer MS; US National Human Genome Research Institute. A vision for the future of genomics research. Nature. 2003 Apr 24;422(6934):835-47. doi: 10.1038/nature01626. Epub 2003 Apr 14. No abstract available.

Reference Type RESULT
PMID: 12695777 (View on PubMed)

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456-88. doi: 10.1016/j.fertnstert.2008.06.035. Epub 2008 Oct 23.

Reference Type RESULT
PMID: 18950759 (View on PubMed)

Sun L, Hu W, Liu Q, Hao Q, Sun B, Zhang Q, Mao S, Qiao J, Yan X. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res. 2012 May 4;11(5):2937-46. doi: 10.1021/pr3000317. Epub 2012 Apr 13.

Reference Type RESULT
PMID: 22428626 (View on PubMed)

Atiomo W, Daykin CA. Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study. Mol Hum Reprod. 2012 Nov;18(11):546-53. doi: 10.1093/molehr/gas029. Epub 2012 Jul 18.

Reference Type RESULT
PMID: 22809877 (View on PubMed)

Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramirez M, Lasuncion MA, Correig X. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem. 2012 Jun;58(6):999-1009. doi: 10.1373/clinchem.2011.176396. Epub 2012 Mar 16.

Reference Type RESULT
PMID: 22427353 (View on PubMed)

Zhao X, Xu F, Qi B, Hao S, Li Y, Li Y, Zou L, Lu C, Xu G, Hou L. Serum metabolomics study of polycystic ovary syndrome based on liquid chromatography-mass spectrometry. J Proteome Res. 2014 Feb 7;13(2):1101-11. doi: 10.1021/pr401130w. Epub 2014 Jan 24.

Reference Type RESULT
PMID: 24428203 (View on PubMed)

Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011 Mar 1;95(3):1073-9.e1-11. doi: 10.1016/j.fertnstert.2010.12.027. Epub 2011 Jan 17.

Reference Type RESULT
PMID: 21247558 (View on PubMed)

Gaster M, Nehlin JO, Minet AD. Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: marker or maker of the diabetic phenotype? Arch Physiol Biochem. 2012 Jul;118(3):156-89. doi: 10.3109/13813455.2012.656653. Epub 2012 Mar 5.

Reference Type RESULT
PMID: 22385297 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://dx.doi.org/10.1016/j.cca.2015.06.008

Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS

http://dx.doi.org/10.1016/j.steroids.2011.12.002

Metabonomic analysis and biomarker screening of serum for polycystic ovary syndrome patients with phlegm-dampness syndrome

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dunjingjing

Identifier Type: -

Identifier Source: org_study_id